Structured evidence table for Magnesium Taurate Cognition Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Magnesium Taurate Cognition Randomized Trial | Based on the NSTEA questionnaire, 73% of participants rated the Overall Benefit as Moderate, Good, or Great, with scores that were substantially higher than the NSTEA study found for multi-vitamins, the average of 58 nutraceuticals, and the average of 28 psychiatric and seizure medications. | 4 | Adams JB (2022) | Vitamin/mineral/micronutrient supplement for autism spectrum disorders: a research survey. |
| Magnesium Taurate Cognition Randomized Trial | Sub-analysis found that the Overall Benefit of ANRC-EP was not significantly affected by gender, age, autism severity, diet quality, self-limited diet, use of psychiatric or seizure medications, dosage, developmental history, intellectual disability, or seizures. | 4 | Adams JB (2022) | Vitamin/mineral/micronutrient supplement for autism spectrum disorders: a research survey. |
| Magnesium Taurate Cognition Randomized Trial | Conclusions This study found that ANRC-EP had significant benefits for a wide range of symptoms, and low adverse effects. | 4 | Adams JB (2022) | Vitamin/mineral/micronutrient supplement for autism spectrum disorders: a research survey. |
| Magnesium Taurate Cognition Randomized Trial | Background Vitamin and mineral supplements are widely used by children and adults diagnosed with autism spectrum disorder (ASD). | 4 | Adams JB (2022) | Vitamin/mineral/micronutrient supplement for autism spectrum disorders: a research survey. |
Source documents